Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881009 · ClinicalTrials.gov registry record · NA
Medtronic Minimed Overnight Closed-Loop System
A NA study of Diabetes Mellitus, Type 1 and Type 1 Diabetes Mellitus, sponsored by Bruce A. Buckingham.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01881009: Completed NA study of Diabetes Mellitus, Type 1 and Type 1 Diabetes Mellitus, sponsored by Bruce A. Buckingham.
NCT01881009 is a NA study of Diabetes Mellitus, Type 1 and Type 1 Diabetes Mellitus that has completed, run by Bruce A. Buckingham. The registered enrollment target is 37 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01881009, a NA study of Diabetes Mellitus, Type 1 and Type 1 Diabetes Mellitus, has completed, sponsored by Bruce A. Buckingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a closely monitored 12 hour overnight inpatient study. Once the safety of the device has been validated we will move the study to an outpatient diabetes camp setting. The camp setting will allow us to obtain pilot efficacy and safety data in a "real-life" environment. We plan to compare the subject control nights to the subject nights on the OCL system to assess the percent of sensor glucose readings in the target range of 70-150 mg/dl. Based on previous research, we anticipate that the use of the OCL system will contribute to a greater percentage of sensor glucose readings in the target range.
Primary Outcome
Compared to control nights, the percent of time in the target range of 70-150 mg/dl according to sensor glucose readings.
Conditions Studied
Interventions
- DEVICE Hybrid Closed-loop System
- DEVICE Sensor-augmented pump
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-08-03 |
| Phase | NA |
What the finished NCT01881009 record still lists
NCT01881009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Hybrid Closed-loop System is the first listed.
NCT01881009 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01881009 about?
NCT01881009 is a clinical study titled "Medtronic Minimed Overnight Closed-Loop System". To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a closely monitored 12 hour overnight inpatient study. Once the safety of the device has been validated we will move the study to an outpatient diabetes camp setting. The camp setting will allow us to obtain pilot...
What is the current status of trial NCT01881009?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2013-06. Estimated completion is 2013-08-03.
What conditions does trial NCT01881009 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus, Autoimmune Diabetes, Juvenile-Onset Diabetes.
What interventions are being tested in trial NCT01881009?
The interventions under investigation include: Hybrid Closed-loop System (DEVICE), Sensor-augmented pump (DEVICE).
Who is sponsoring clinical trial NCT01881009?
This trial is sponsored by Bruce A. Buckingham, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01881009 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01881009's enrollment target sits among peer trials
37 84th of 118 higher than 32 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
RECRUITING · NA
-
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
RECRUITING · NA
-
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia